The SETBP1-HD MICROGRANT PROGRAM from the SETBP1 Society supports investigator-led research to broaden our understanding of SETBP1 loss-of-function biology and develop safe and transformative therapies for SETBP1 haploinsufficiency disorder.
The purpose of this funding opportunity announcement is to support novel research investigating altered molecular pathways, including the unknown role of phosphorylation and the identification of potential treatments for SETBP1-HD. Through the support provided with this microgrant, the SETBP1 Society expects to address critical knowledge gaps underlying SETBP1 loss-of-function while facilitating research studies for the ultra-rare SETBP1-HD and fostering new scientific collaborations within the community.
Proposals should focus on:
1. Uncovering molecular pathways at the tissue or cellular level altered in SETBP1 loss-of-function contributing to neurodevelopmental phenotypes in SETBP1-HD.
2. Identifying novel drug candidates or treatments for SETBP1-HD.
ELIGIBILITY
The SETBP1 Society microgrant program is open to research investigators affiliated with an academic institution, hospital system, non-profit institution, or other accredited research institutions based in the United States (U.S.) or internationally. Eligible applicants include postdoctoral fellows, clinical fellows, researchers, physicians, or other associated research professionals with faculty appointments or research positions.
GRANT DETAILS
SETBP1 Society currently is funding microgrants which are intended to fund small proof-of-concept studies aimed at collecting supportive data for subsequent research initiatives and funding. Applicants may request up to $25,000 direct costs to be expended within a 12-month period. SETBP1 Society does not support indirect costs for Grants.
Letters of intent are due on August 2, 2024 and full proposals are due on September 16, 2024.